Health Canada Approves AGAMREE (vamorolone) as the First Treatment for Duchenne Muscular Dystrophy in Canada
Kye Pharmaceuticals announced that Health Canada has approved AGAMREE (vamorolone) for the treatment of Duchenne Muscular Dystrophy (DMD) in boys age 4 and older....
Tevard Biosciences Presents Data Demonstrating Production of Full-Length Protein with tRNA-Based Therapy for Duchenne Muscular Dystrophy
Tevard Biosciences announced the presentation of new preclinical data showing potent restoration of full-length functional proteins in models of Duchenne muscular dystrophy (DMD) and...
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
Dyne Therapeutics announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted Orphan Drug designation for DYNE-251 in individuals with...
Satellos submits IND to FDA for Phase 2 SAT-3247 Clinical Trial in Duchenne Muscular Dystrophy
Satellos Bioscience announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), along with parallel regulatory...
FDA Grants Orphan Drug Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy
Nippon Shinyaku announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to NS-051/NCNP-04 which is being developed for the...